CFG
PCRX icon

Citizens Financial Group’s Pacira BioSciences PCRX Stock Holding History

Citizens Financial Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-149
Closed -$7K – 592
2017
Q1 		$7K Buy
149
+21
+16% +$908 ﹤0.01% 472
2016
Q4 		$4K Hold
128
– – ﹤0.01% 554
2016
Q3 		$4K Buy
+128
New +$5.01K ﹤0.01% 565

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
DCM
Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Citizens Financial Group's PCRX Position: Q2 2017 in Review

Citizens Financial Group sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 149 shares — an estimated $7K sold.

Citizens Financial Group first reported a position in PCRX in Q3 2016 and held it in 3 quarters. The position peaked at $7K in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

  • Citizens Financial Group reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
  • Citizens Financial Group sold 149 Pacira BioSciences shares in Q2 2017, an estimated $7K.
  • Citizens Financial Group first reported a position in Pacira BioSciences in Q3 2016 and held it in 3 quarters.
  • Citizens Financial Group's Pacira BioSciences position peaked at $7K in Q1 2017.
  • 196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on Citizens Financial Group's 13F filing for Q2 2017, filed 10 Aug 2017.